We sought to determine predictors of treatment failure, significant post-RAI dysthyroidism, weight gain and the development of thyroid eye disease. Finally, we sought to assess treatment satisfaction, thyroid symptoms and factors predicting adverse symptomatic outcomes.
| ME THODS

| Patients
Every patient receiving RAI for Graves' disease (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) at the Edinburgh Centre for Endocrinology & Diabetes was identified from our comprehensive registry (n = 665 episodes, 74.5% female).
Graves' disease was diagnosed on the basis of elevated free thyroxine (fT4), fully suppressed TSH and elevated TSH receptor antibodies (TRAbs). Where TRAb was negative, the diagnosis was based on technetium-99 m scintigraphy (n = 23). Ethical approval was granted by the Greater Manchester South Research Ethics Committee with respect to the patient questionnaire element of this project.
| Therapy
Standard practice in our unit was to administer a fixed dose of 400 MBq RAI. Occasionally, a fixed dose of 800 MBq was employed, principally following earlier treatment failure with 400 MBq (n = 43). Patients pre-treated with thionamides were asked to discontinue therapy 5 days prior to RAI. Where a decision to reinstitute thionamide was made, this was done 3-5 days after RAI. Subsequent thyroid function test monitoring was typically performed within 8 weeks following treatment and every 4-8 weeks thereafter. The limit of quantification for TSH was 0.01 mU/L and for the purposes of statistical analysis any value reported as <0.01 mU/L was assigned the value 0. The limit of quantification for fT4 was 5 pmol/L and values lower than this were assigned the value 4 pmol/L for statistical analysis. The reference range for fT4 was 9-21 pmol/L and for TSH was 0.2-4.5 mU/L. TRAb measurements were performed using the second-generation BRAHM Lumitest TRAK assay (BRAHMS Diagnostica, Berlin, Germany) until 2008 (52% of subjects) and thereafter by a Roche assay performed on the Cobas E411 analytical platform (Roche Diagnostics, West Sussex, UK).
| Assays
8 No significant differences have been noted between these TRAb assays. Ten of 474 patients (2.1%) were admitted to hospital for unscheduled care in the first 100 days following RAI. Two admissions were related to new atrial fibrillation and 1 to uncontrolled atrial fibrillation, diagnosed prior to RAI. The only biochemical parameter which significantly differed in those admitted to hospital was lower fT4 at diagnosis (22 [17] [18] [19] [20] [21] [22] [23] [24] vs 32 [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] pmol/L, P = 0.008).
| Outcomes
| Treatment failure
Differences between individuals with treatment failure and success after a first dose of RAI are summarized in Table 1 . With increasing TRAb concentration, either at diagnosis or immediately before RAI, the chances of treatment failure increased (Table 2) . Table S1 ). Gender, age and pre-RAI thionamide were not independently associated with treatment failure.
Of those receiving a first dose of RAI, 553 (96.0%) were given 400 MBq, with only 23 (4.0%) receiving 800 MBq (age and fT4 at diagnosis were not different although TRAb was significantly higher in the 800 MBq group, P = 0.03). RAI dose was not associated with a significant difference in treatment failure, either in those receiving a first or second dose of RAI, although the number of patients was too small to definitively address this question.
| Weight gain
Weight change data at 1-year post-RAI was available in 228 of 587 and 31.1% gained >10%. Median weight gain in those with a pre-RAI fT4 within or below the reference range was 3.2 kg (1.3-6.0) and 5.8 kg (2.6-9.8) for those with an elevated fT4 prior to RAI (P < 0.001).
Higher fT4 prior to RAI, RAI administration within 6 months of diagnosis and the absence of thionamide treatment prior to RAI were all associated with weight gain (Table 3) . Nadir fT4 below the reference range after RAI was associated with weight gain along with a non-significant trend towards lower median nadir fT4 concentration in those gaining more than 5 kg. However, logistic regression (Table S2) 
| Thyroid eye disease
New TED developed post-RAI in 45/620 (7.3%) episodes of treatment (45/587 [7.6%] individuals). Higher fT4 prior to RAI was associated with the risk of newly developing TED although no other significant associations were noted (Table 4) . When limiting the analysis to the 35 patients who were referred to the multi-disciplinary TED clinic for new TED after RAI, no significant differences were noted in relation to all the parameters assessed in Table 5 . A total of 13 patients (2.2% of total cohort), with new post-RAI TED, required active treatment with systemic glucocorticoid therapy (n = 13), orbital radiotherapy (n = 4) or orbital decompression surgery (n = 6).
No significant differences in biochemical or clinical parameters were noted between this group when compared to the total cohort (not reported). Cigarette smoking was associated with pre-RAI TED (15.6% vs 6.3%, P < 0.001) but development of new TED was not significantly associated with smoking status (OR: 1.52, P = 0.191).
| Questionnaire responses
Of 509 (34.4%), 175 eligible individuals responded to the RAI questionnaire; there were no significant differences in demographic, biochemical or outcome data between responders and non-responders. The median interval from final RAI to questionnaire response was 62 (32-95) months. On a scale from 1 (dissatisfied) to 10 (very satisfied), the median response was 8 (6) (7) (8) (9) (10) for the question "How do you feel about having had treatment with RAI?" On a scale from 1 (unwell) to 10 (very well), the median response to the question "How well did you feel in the first 12 months after treatment with RAI?" was 7 (5-10; Figure S1 ).
Of the respondents, 78.9% would recommend RAI to a friend.
Neither pre-or post-RAI biochemical parameters nor self-reported weight change were associated with any treatment satisfaction measures. Median self-reported weight change at 1 year was +6.0 kg (3.7-10). Of the respondents, 18.2% were happy with TA B L E 3 Differences between those gaining in weight following their final radioiodine (RAI) treatment and those who did not gain weight (or gained ≤5 kg) The frequency of thyroid symptoms occurring following RAI is reported in Table 5 . Responses to individual components of the thyroid symptom questionnaire (or total score) were not associated with any biochemical parameters prior to or after RAI, nor were they associated with any treatment outcome measures. These symptoms were also not related to the median of the three most recent TSH and fT4 measurements during levothyroxine replacement (not reported).
| D ISCUSS I ON
We have presented one of the largest and most detailed cohorts of patients with Graves' disease treated with RAI, reflecting modern practice in the United Kingdom. Several previous investigators have assessed outcomes following RAI in Graves'. 3, 7, 12 This comprehensive report addresses many of the current key questions facing endocrinologists using RAI in Graves' disease.
| Treatment failure
We of TRAb [13] [14] [15] ; however, the results from our large cohort are unequivocal and independent of other confounding variables. This also raises the question of whether higher doses of RAI should be employed in patients with higher risk of failure, although the evidence base supporting the efficacy of this approach is scant. In a retrospective study of 258 patients, success rates were lower with doses <555 MBq (74%) vs doses >777 MBq (89%). 16 Others have investigated adjunctive therapy with lithium to increase treatment success and this is worthy of further investigation. 17 The other features associated with treatment failure, like TRAb, are all surrogates of underlying disease activity. Higher free T4 at diagnosis, but not immediately before RAI (when many patients have been pre-treated with thionamide), was significantly associated with failure, as has previously been reported. 3 Finally, the prescription of thionamide after (but not before) RAI was an independent risk factor for failure; a strategy often reserved for select patients where concerns exist regarding significant post-RAI thyrotoxic flare. Our finding that pre-RAI thionamide is not independently associated with treatment failure is consistent with a number of previous investigators 18, 19 and is reassuring.
| Weight gain
The majority of our RAI-treated patients experienced weight gain and although this was less marked when pre-treatment fT4 was normal, these patients still gained an average 3.2 kg in 1 year. In total, almost 20% of patients gained more than 10 kg in the first year after RAI. As there was a slight bias towards lower nadir fT4 and higher peak TSH in those with weight data available, it is possible that these data may slightly overestimate weight gain, although this effect is likely to be marginal and our findings are broadly consistent with previous data 4 . Like previous assessments of weight gain, these findings are also limited by the absence of weight data prior to the diagnosis centration. 21 The majority of respondents to our questionnaire were unhappy with their weight change post-RAI.
| Thyroid eye disease
In contrast to previous studies, 22 we were unable to demonstrate any significant association with post-RAI dysthyroidism and the development of TED. This may reflect changes in patient selection (fewer high-risk patients) in the modern era. Although the proportion of patients developing new TED in our study (7.3%) was similar to previously published series, 23 the proportion requiring glucocorticoids, orbital radiotherapy or surgery appeared substantially lower than this historical comparator. Cigarette smoking was significantly associated with prior TED but not newly developing TED after RAI. There were non-significant trends hinting towards an association with smoking and higher TSH although it is notable that no relationship appeared to exist with respect to nadir fT4. Even when selecting out for patients referred to our multi-disciplinary thyroid eye clinic or patients requiring systemic glucocorticoid, orbital radiotherapy or decompression surgery, we were unable to detect significant differences in post-RAI dysthroidism. Whilst it could be argued our study is underpowered with respect to TED outcomes, the sample size is larger than previous interventional 23 and observational studies 5 which have reported significant differences.
| Patient-reported outcomes
We had hypothesized that the extent of post-RAI hypothyroidism may have an adverse long-term symptomatic impact. This was not borne out by the responses to our questionnaire, which showed no differences in symptoms based on thyroid biochemistry before or after RAI. The frequency of hypothyroid type symptoms was considerable in our cohort. However, this study lacks a matched control group, making it difficult to draw conclusions about the direct contribution of RAI. It is also conceivable that a selection bias existed, with more symptomatic individuals more likely to respond to the questionnaire. Transient hypothyroidism is unequivocally associated with a negative impact on quality of life 20 and others have shown that levothyroxine-treated patients have higher incidence of psychological distress, despite TSH and fT4 concentration within the normal range. 24, 25 We found no association with thyroid symptoms or treatment satisfaction relating to most recent thyroid function (median of last three tests) or levothyroxine dose in our cohort. Despite the frequency of reported symptoms, the vast majority of patients receiving RAI were positively disposed towards their treatment and satisfaction was, again, not associated with thyroid biochemistry.
| Summary
Insights gleaned from this cohort are likely to be useful to endocri- Prospective, multi-centre, national data collection or large randomized controlled trials are long overdue.
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